1. Drug Policy in the Czech Republic
Jana Skoupá, MD 
Value in Health Regional Issues 
Volume 13, Pages (September 2017)
DOI: /j.vhri
Copyright © Terms and Conditions

2. Fig. 1
Simplified structure of the P&R process for outpatient drugs in the Czech Republic. HTA, health technology assessment; P&R, pricing and reimbursement; RWE, real-world evidence.
Value in Health Regional Issues  , 55-58DOI: ( /j.vhri )
Copyright © Terms and Conditions

3. Fig. 2
Mean duration (d) of the P&R process in the Czech Republic per Anatomical Therapeutic Chemical classification system group. Numbers in parentheses indicate the number of individual proceedings. Labels: A, alimentary tract and metabolism; B, blood and blood-forming organs; C, cardiovascular system; D, dermatologicals; G, genitourinary system and sex hormones; H, systemic hormonal prep, excluding sex hormones; J, general anti-infectives for systemic use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products; R, respiratory system; S, sensory organs; V, various. P&R, pricing and reimbursement.
Value in Health Regional Issues  , 55-58DOI: ( /j.vhri )
Copyright © Terms and Conditions